Flavonoids represent a structurally diverse class of polyphenolic compounds derived from medicinal plants that have emerged as promising pharmacological agents and drug development leads. With over 10,000 naturally occurring structures classified into major subclasses including flavones, flavonols, flavanones, flavanonols, isoflavones, and anthocyanidins, these compounds exhibit remarkable chemical diversity that translates into distinct pharmacological profiles. Contemporary research has elucidated multiple molecular mechanisms underlying flavonoid bioactivity, including enzyme inhibition, receptor modulation, and regulation of critical signaling pathways involved in oxidative stress, inflammation, apoptosis, and metabolic homeostasis. Structure-activity relationship studies have identified key pharmacophores responsible for target selectivity and potency across therapeutic areas including oncology, cardiovascular disease, neurodegenerative disorders, metabolic syndrome, and infectious diseases. Despite compelling preclinical evidence, translation of flavonoids into clinically viable therapeutics faces significant challenges related to poor oral bioavailability, extensive first-pass metabolism, and limited target tissue accumulation. Innovative strategies including structural modification, prodrug design, nanoformulation, and combination therapy approaches are being explored to optimize the drug-likeness properties of lead flavonoids. This review critically examines the pharmacological potential of plant-derived flavonoids through the lens of modern drug discovery, emphasizing validated molecular targets, disease-modifying mechanisms, and translational development strategies. Understanding the pharmacological basis of flavonoid activity will facilitate rational design of next-generation therapeutics that leverage the chemical scaffold diversity inherent to this natural product class.